滅菌注射剤の世界市場2023-2031:産業分析、規模、シェア、成長、動向、予測

• 英文タイトル:Sterile Injectable Drugs Market [Drug Class: Monoclonal Antibodies (Mabs), Cytokines, Insulin, Peptide Hormones, Vaccine, Immunoglobulins, Blood Factors, Peptide Antibodies and Others] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Sterile Injectable Drugs Market [Drug Class: Monoclonal Antibodies (Mabs), Cytokines, Insulin, Peptide Hormones, Vaccine, Immunoglobulins, Blood Factors, Peptide Antibodies and Others] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031「滅菌注射剤の世界市場2023-2031:産業分析、規模、シェア、成長、動向、予測」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2403B366
• 出版社/出版日:Transparency Market Research / 2024年1月
• レポート形態:英文、PDF、222ページ
• 納品方法:受注後3営業日
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Corporate License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
滅菌注射剤市場 - レポートの範囲
TMRの調査レポート「滅菌注射剤の世界市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界の滅菌注射剤市場の収益を提供しています。また、2023年から2031年までの滅菌注射剤の世界市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照し、滅菌注射剤市場に関連する認知症を理解した。

二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の滅菌注射剤市場の様々な属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、同レポートは、滅菌注射剤の世界市場における競争力学の変化に光を投げかけています。これらは、既存の市場関係者だけでなく、滅菌注射剤の世界市場への参入に関心のある企業にとっても貴重なツールとなります。

当レポートでは、滅菌注射剤の世界市場の競争環境について掘り下げています。滅菌注射剤の世界市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている滅菌注射剤の世界市場におけるプレイヤーの属性です。

滅菌注射剤の世界市場レポートが回答した主な質問
- 予測期間中の全地域における滅菌注射剤が生み出す売上高/収益は?
- 滅菌注射剤の世界市場におけるビジネスチャンスは?
- 市場の主な促進要因、阻害要因、機会、脅威は何か?
- 予測期間中に最も速いCAGRで拡大する地域市場はどこか?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは?
- 世界市場で事業展開する各企業の市場ポジションは?

滅菌注射剤市場 - 調査目的と調査アプローチ
滅菌注射剤の世界市場に関する包括的なレポートは、まず概要から始め、次に調査範囲と目的について説明します。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと流通業者、製品承認に関する規制シナリオについて詳細に解説しています。

本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えます。また、過去と予測期間末の主要セグメントの市場シェアの比較も可能です。

当レポートでは、滅菌注射剤の世界市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は滅菌注射剤の世界市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。

1. 序論
2. 仮定・調査手法
3. エグゼクティブサマリー:世界の滅菌注射剤市場
4. 市場概要
5. 主要インサイト
6. 世界の滅菌注射剤市場分析・予測:種類別
7. 世界の滅菌注射剤市場分析・予測:薬剤クラス別
8. 世界の滅菌注射剤市場分析・予測:疾患別
9. 世界の滅菌注射剤市場分析・予測:流通チャネル別
10. 世界の滅菌注射剤市場分析・予測:地域別
11. 北米の滅菌注射剤市場分析・予測
12. ヨーロッパの滅菌注射剤市場分析・予測
13. アジア太平洋の滅菌注射剤市場分析・予測
14. 中南米の滅菌注射剤市場分析・予測
15. 中東/アフリカの滅菌注射剤市場分析・予測
16. 競争状況

レポート目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sterile Injectable Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Sterile Injectable Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Type/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Sterile Injectable Drugs Market Analysis and Forecast, by Type
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Type, 2017–2031
        6.3.1. Small Molecule
        6.3.2. Large Molecule
    6.4. Market Attractiveness, by Type
7. Global Sterile Injectable Drugs Market Analysis and Forecast, by Drug Class
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Drug Class, 2017–2031
        7.3.1. Monoclonal Antibodies (Mabs)
        7.3.2. Cytokines
        7.3.3. Insulin
        7.3.4. Peptide Hormones
        7.3.5. Vaccine
        7.3.6. Immunoglobulins
        7.3.7. Blood Factors
        7.3.8. Peptide Antibiotics
        7.3.9. Others
    7.4. Market Attractiveness, by Drug Class
8. Global Sterile Injectable Drugs Market Analysis and Forecast, by Indication
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Indication, 2017–2031
        8.3.1. Cardiology & Metabolic Disorders
        8.3.2. Neurology
        8.3.3. Oncology
        8.3.4. Autoimmune
        8.3.5. Gastroenterology
        8.3.6. Hematology
        8.3.7. Pain
        8.3.8. Infectious Disease
        8.3.9. Others
    8.4. Market Attractiveness, by Indication
9. Global Sterile Injectable Drugs Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Distribution Channel, 2017–2031
        9.3.1. Hospital Pharmacy
        9.3.2. Retail Pharmacy
        9.3.3. E-commerce
    9.4. Market Attractiveness, by Distribution Channel
10. Global Sterile Injectable Drugs Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017–2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Region
11. North America Sterile Injectable Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Type, 2017–2031
        11.2.1. Small Molecule
        11.2.2. Large Molecule
    11.3. Market Attractiveness, by Type
    11.4. Market Value Forecast, by Drug Class, 2017–2031
        11.4.1. Monoclonal Antibodies (Mabs)
        11.4.2. Cytokines
        11.4.3. Insulin
        11.4.4. Peptide Hormones
        11.4.5. Vaccine
        11.4.6. Immunoglobulins
        11.4.7. Blood Factors
        11.4.8. Peptide Antibiotics
        11.4.9. Others
    11.5. Market Attractiveness, by Drug Class
    11.6. Market Value Forecast, by Indication, 2017–2031
        11.6.1. Cardiology & Metabolic Disorders
        11.6.2. Neurology
        11.6.3. Oncology
        11.6.4. Autoimmune
        11.6.5. Gastroenterology
        11.6.6. Hematology
        11.6.7. Pain
        11.6.8. Infectious Disease
        11.6.9. Others
    11.7. Market Attractiveness, by Indication
    11.8. Market Value Forecast, by Distribution Channel, 2017–2031
        11.8.1. Hospital Pharmacy
        11.8.2. Retail Pharmacy
        11.8.3. E-commerce
    11.9. Market Attractiveness, by Distribution Channel
    11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.10.1. U.S.
        11.10.2. Canada
    11.11. Market Attractiveness Analysis
        11.11.1. By Type
        11.11.2. By Drug Class
        11.11.3. By Indication
        11.11.4. By Distribution Channel
        11.11.5. By Country
12. Europe Sterile Injectable Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Type, 2017–2031
        12.2.1. Small Molecule
        12.2.2. Large Molecule
    12.3. Market Attractiveness, by Type
    12.4. Market Value Forecast, by Drug Class, 2017–2031
        12.4.1. Monoclonal Antibodies (Mabs)
        12.4.2. Cytokines
        12.4.3. Insulin
        12.4.4. Peptide Hormones
        12.4.5. Vaccine
        12.4.6. Immunoglobulins
        12.4.7. Blood Factors
        12.4.8. Peptide Antibiotics
        12.4.9. Others
    12.5. Market Attractiveness, by Drug Class
    12.6. Market Value Forecast, by Indication, 2017–2031
        12.6.1. Cardiology & Metabolic Disorders
        12.6.2. Neurology
        12.6.3. Oncology
        12.6.4. Autoimmune
        12.6.5. Gastroenterology
        12.6.6. Hematology
        12.6.7. Pain
        12.6.8. Infectious Disease
        12.6.9. Others
    12.7. Market Attractiveness, by Indication
    12.8. Market Value Forecast, by Distribution Channel, 2017–2031
        12.8.1. Hospital Pharmacy
        12.8.2. Retail Pharmacy
        12.8.3. E-commerce
    12.9. Market Attractiveness, by Distribution Channel
    12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.10.1. Germany
        12.10.2. U.K.
        12.10.3. France
        12.10.4. Italy
        12.10.5. Spain
        12.10.6. Rest of Europe
    12.11. Market Attractiveness Analysis
        12.11.1. By Type
        12.11.2. By Drug Class
        12.11.3. By Indication
        12.11.4. By Distribution Channel
        12.11.5. By Country/Sub-region
13. Asia Pacific Sterile Injectable Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Type, 2017–2031
        13.2.1. Small Molecule
        13.2.2. Large Molecule
    13.3. Market Attractiveness, by Type
    13.4. Market Value Forecast, by Drug Class, 2017–2031
        13.4.1. Monoclonal Antibodies (Mabs)
        13.4.2. Cytokines
        13.4.3. Insulin
        13.4.4. Peptide Hormones
        13.4.5. Vaccine
        13.4.6. Immunoglobulins
        13.4.7. Blood Factors
        13.4.8. Peptide Antibiotics
        13.4.9. Others
    13.5. Market Attractiveness, by Drug Class
    13.6. Market Value Forecast, by Indication, 2017–2031
        13.6.1. Cardiology & Metabolic Disorders
        13.6.2. Neurology
        13.6.3. Oncology
        13.6.4. Autoimmune
        13.6.5. Gastroenterology
        13.6.6. Hematology
        13.6.7. Pain
        13.6.8. Infectious Disease
        13.6.9. Others
    13.7. Market Attractiveness, by Indication
    13.8. Market Value Forecast, by Distribution Channel, 2017–2031
        13.8.1. Hospital Pharmacy
        13.8.2. Retail Pharmacy
        13.8.3. E-commerce
    13.9. Market Attractiveness, by Distribution Channel
    13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.10.1. China
        13.10.2. Japan
        13.10.3. India
        13.10.4. Australia & New Zealand
        13.10.5. Rest of Asia Pacific
    13.11. Market Attractiveness Analysis
        13.11.1. By Type
        13.11.2. By Drug Class
        13.11.3. By Indication
        13.11.4. By Distribution Channel
        13.11.5. By Country/Sub-region
14. Latin America Sterile Injectable Drugs Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Type, 2017–2031
        14.2.1. Small Molecule
        14.2.2. Large Molecule
    14.3. Market Attractiveness, by Type
    14.4. Market Value Forecast, by Drug Class, 2017–2031
        14.4.1. Monoclonal Antibodies (Mabs)
        14.4.2. Cytokines
        14.4.3. Insulin
        14.4.4. Peptide Hormones
        14.4.5. Vaccine
        14.4.6. Immunoglobulins
        14.4.7. Blood Factors
        14.4.8. Peptide Antibiotics
        14.4.9. Others
    14.5. Market Attractiveness, by Drug Class
    14.6. Market Value Forecast, by Indication, 2017–2031
        14.6.1. Cardiology & Metabolic Disorders
        14.6.2. Neurology
        14.6.3. Oncology
        14.6.4. Autoimmune
        14.6.5. Gastroenterology
        14.6.6. Hematology
        14.6.7. Pain
        14.6.8. Infectious Disease
        14.6.9. Others
    14.7. Market Attractiveness, by Indication
    14.8. Market Value Forecast, by Distribution Channel, 2017–2031
        14.8.1. Hospital Pharmacy
        14.8.2. Retail Pharmacy
        14.8.3. E-commerce
    14.9. Market Attractiveness, by Distribution Channel
    14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.10.1. Brazil
        14.10.2. Mexico
        14.10.3. Rest of Latin America
    14.11. Market Attractiveness Analysis
        14.11.1. By Type
        14.11.2. By Drug Class
        14.11.3. By Indication
        14.11.4. By Distribution Channel
        14.11.5. By Country/Sub-region
15. Middle East & Africa Sterile Injectable Drugs Market ;Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Type, 2017–2031
        15.2.1. Small Molecule
        15.2.2. Large Molecule
    15.3. Market Attractiveness, by Type
    15.4. Market Value Forecast, by Drug Class, 2017–2031
        15.4.1. Monoclonal Antibodies (Mabs)
        15.4.2. Cytokines
        15.4.3. Insulin
        15.4.4. Peptide Hormones
        15.4.5. Vaccine
        15.4.6. Immunoglobulins
        15.4.7. Blood Factors
        15.4.8. Peptide Antibiotics
        15.4.9. Others
    15.5. Market Attractiveness, by Drug Class
    15.6. Market Value Forecast, by Indication, 2017–2031
        15.6.1. Cardiology & Metabolic Disorders
        15.6.2. Neurology
        15.6.3. Oncology
        15.6.4. Autoimmune
        15.6.5. Gastroenterology
        15.6.6. Hematology
        15.6.7. Pain
        15.6.8. Infectious Disease
        15.6.9. Others
    15.7. Market Attractiveness, by Indication
    15.8. Market Value Forecast, by Distribution Channel, 2017–2031
        15.8.1. Hospital Pharmacy
        15.8.2. Retail Pharmacy
        15.8.3. E-commerce
    15.9. Market Attractiveness, by Distribution Channel
    15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.10.1. GCC Countries
        15.10.2. South Africa
        15.10.3. Rest of Middle East & Africa
    15.11. Market Attractiveness Analysis
        15.11.1. By Type
        15.11.2. By Drug Class
        15.11.3. By Indication
        15.11.4. By Distribution Channel
        15.11.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Baxter International
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Type Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Sanofi S.A
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Type Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Pfizer, Inc.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Type Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. GlaxoSmithKline Plc.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Type Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. AstraZeneca
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Type Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Merck & Co., Inc.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Type Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Novartis AG
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Type Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Johnson & Johnson Services, Inc.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Type Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Novo Nordisk A/S
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Type Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Gilead Sciences, Inc.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Type Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview

List of Tables

Table 01: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 02: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 03: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 05: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 08: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 09: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 10: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 11: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 13: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 14: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 15: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 18: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 23: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 24: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 25: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 26: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 28: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 29: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 30: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031


• 英文レポート名:Sterile Injectable Drugs Market [Drug Class: Monoclonal Antibodies (Mabs), Cytokines, Insulin, Peptide Hormones, Vaccine, Immunoglobulins, Blood Factors, Peptide Antibodies and Others] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
• 日本語訳:滅菌注射剤の世界市場2023-2031:産業分析、規模、シェア、成長、動向、予測
• レポートコード:MRC2403B366お問い合わせ(見積依頼・ご注文・質問)